RecruitingPhase 1NCT03425526
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Studying Adenovirus infection in immunocompromised patients
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- David Marin, MSW, ASWM.D. Anderson Cancer Center
- Intervention
- Allogeneic Adenovirus-specific Cytotoxic T Lymphocytes(biological)
- Enrollment
- 16 enrolled
- Eligibility
- All sexes
- Timeline
- 2018 – 2027
Study locations (1)
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03425526 on ClinicalTrials.govOther trials for Adenovirus infection in immunocompromised patients
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05101213Study Assessing the Feasibility, Safety and Efficacy of Genetically Engineered Glucocorticoid Receptor Knock Out Virus Specific CTL Lines for Viral Infections in Immunosuppressed Cancer PatientsM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04364178Viral Specific T-Lymphocytes to Treat Adenovirus or CMVJessie L. Alexander
See all trials for Adenovirus infection in immunocompromised patients →